XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ORDINARY SHARE AND SHARE INCENTIVE PLANS
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
ORDINARY SHARE AND SHARE INCENTIVE PLANS

NOTE 9-ORDINARY SHARE AND SHARE INCENTIVE PLANS

Stock Incentive Plans

On June 28, 2022, shareholders of the Company approved the amendment of authorized share capital of the Company by the consolidation of the existing 250,000,000 ordinary shares of $0.00375 par value each into 62,500,000 ordinary shares of $0.015 par value each. As a result, the one-for-four reverse split of the Company’s ordinary shares became effective on June 28 2022, as of 4:30 p.m. Eastern Time with trading commenced on the post-reverse split-adjusted basis on the NASDAQ Global Select Market as of the opening of trading on Wednesday, June 29, 2022. All shares/per share related data in this note have been adjusted retroactively to reflect the one-for-four reverse share split.

As of December 31, 2023, the Company has the stock incentive plans described below. Substantially all outstanding awards are subject to potential accelerated vesting in the event of a change in control of the Company. The Company repurchases and cancels its ordinary shares forfeited with respect to the tax liability associated with certain vesting of restricted stock and restricted stock unit grants under these plans.

2017 Equity Incentive Plan:

The 2017 Equity Incentive Plan, or (the “2017 Plan”), was approved by the Board of Director on November 4, 2016, and expired on December 31, 2021. The 2017 Plan provides for the grant of the following types of incentive awards: (i) stock options, (ii) stock

appreciation rights, (iii) restricted stock, (iv) restricted stock units, (v) performance shares and performance units, and (vi) other stock or cash awards (“Award,” and collectively, “Awards”). Those who are eligible for Awards under the 2017 Plan include employees, directors and consultants who provide services to the Company and its affiliates.

The maximum aggregate number of shares that may be awarded and sold under the Plan is 2,000,000 Shares (500,000 ordinary shares after taking into consideration of the reverse share split effective on June 28, 2022) plus (i) any shares that, as of December 31, 2016, have been reserved but not issued pursuant to any awards granted under UTStarcom Holdings Corp.’s Amended and Restated 2006 Equity Incentive Plan (the “2006 Plan”), and (ii) any shares subject to stock options or similar awards granted under the 2006 Plan that expire or otherwise terminate without having been exercised in full and Shares issued pursuant to awards granted under the 2006 Plan that are forfeited to or repurchased by the Company. The shares may be authorized but unissued, or reacquired common stock.

On August 10, 2021, the Board of Directors approved an extension and share increase of the 2017 Plan. As a result, the term of the 2017 Plan has been extended to December 31, 2024, and a total number of additional 1,000,000 ordinary shares (250,000 ordinary shares taking into consideration of the reverse share split effective on June 28, 2022) have been added to the 2017 Plan. On November 24, 2022, the Board of Directors approved a further extension and share increase of the 2017 Plan. As a result, the term of the 2017 Plan has been extended to December 31, 2026, and a total number of additional 430,000 ordinary shares have been added to the 2017 Plan.

As of December 31, 2023, 356,600 shares underlying options and restricted stock awards and units were outstanding under the 2017 Plan.

Stock Award and Stock Option Activity

During 2023, the Company granted equity awards primarily consisting of stock option and restricted stock. Such awards generally vest over a period of four years or two years from the vesting start date. Restricted stock has the voting rights of ordinary shares and the shares underlying restricted stock are issued and outstanding. As of December 31, 2023, the number of ordinary shares available for issuance pursuant to future grants under the 2017 plan, including remaining unissued shares under Prior Plans that have been transferred into the 2017 plan were 203,342. The 2006 Plan expired on December 31, 2016, and as of December 31, 2023, 446,200 shares were transferred to the 2017 Plan that was approved by the Board of Director on November 4, 2016. The following table summarizes the Company’s stock option activities:

 

 

 

 

 

 

Weighted

 

 

 

Number of

 

 

average

 

 

 

shares

 

 

exercise

 

 

 

outstanding

 

 

price

 

 

 

(in thousands)

 

 

 

 

Options Outstanding, December 31, 2021

 

 

364

 

 

$

4.47

 

Options granted

 

 

 

 

 

 

Options exercised

 

 

(4

)

 

 

4.52

 

Options forfeited or expired

 

 

(13

)

 

 

6.59

 

Options Outstanding, December 31, 2022

 

 

347

 

 

$

4.39

 

Options granted

 

 

 

 

 

 

Options exercised

 

 

(1

)

 

 

4.28

 

Options cancelled

 

 

(8

)

 

 

4.45

 

Options forfeited or expired

 

 

(16

)

 

 

4.44

 

Options Outstanding, December 31, 2023

 

 

322

 

 

$

4.39

 

 

Under the Plans, the Company granted restricted stock awards. Restricted stock awards are unvested stock awards that may include grants of restricted stock or grants of restricted stock units. Such awards generally vest over a period of four years from the date of grant. Restricted stock has the voting rights of ordinary share and the shares underlying restricted stock are considered to be currently issued and outstanding. Restricted stock units do not have the voting rights of ordinary shares, and the shares underlying the restricted stock units are not considered issued and outstanding. The expense for such awards is based on the fair market value of the shares at the date of grant and is recognized on a straight-line basis over the requisite service period. The grant of restricted stock awards is deducted from

the shares available on a one to one basis for grant under the Company’s stock plan. Unvested restricted awards as of December 31, 2023 and changes during the year ended December 31, 2023 are summarized below:

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

average

 

 

 

 

 

 

grant date

 

 

 

Shares

 

 

fair value

 

 

 

(in thousands)

 

 

 

 

Total nonvested restricted stock at December 31, 2021

 

 

59

 

 

$

9.56

 

Granted

 

 

29

 

 

 

3.97

 

Vested

 

 

(44

)

 

 

9.66

 

Forfeited

 

 

(1

)

 

 

14.82

 

Total nonvested restricted stock at December 31, 2022

 

 

43

 

 

$

5.65

 

Granted

 

 

30

 

 

 

3.79

 

Vested

 

 

(38

)

 

 

5.32

 

Forfeited

 

 

 

 

 

 

Total nonvested restricted stock at December 31, 2023

 

 

35

 

 

$

3.28

 

 

During 2023, approximately 0.04 million shares of restricted stock awards vested. The total fair value of restricted stock awards vested, as measured on the date of vesting, during 2023 was $0.2 million. During 2023, the Company also granted approximately 0.03 million restricted stock awards.

 

During 2022, approximately 0.04 million shares of restricted stock awards vested. The total fair value of restricted stock awards vested, as measured on the date of vesting, during 2022 was $0.4 million. During 2022, the Company also granted approximately 0.03 million restricted stock awards.

The following table summarizes significant ranges of outstanding and exercisable stock options as of December 31, 2023:

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of shares

 

 

Average

 

 

Weighted

 

 

Number of shares

 

 

Weighted

 

Range of

 

 

Outstanding

 

 

Remaining

 

 

Average

 

 

Exercisable

 

 

Average

 

Exercise Prices

 

 

as of 12/31/2023

 

 

Contractual Term

 

 

Exercise Price

 

 

as of 12/31/2023

 

 

Exercise Price

 

$

4.28

 

 

$

4.28

 

 

 

194,777

 

 

4.92

 

 

$

4.28

 

 

 

194,777

 

$

4.28

 

$

4.56

 

 

$

4.56

 

 

 

127,019

 

 

 

3.92

 

 

$

4.56

 

 

 

127,019

 

 

$

4.56

 

 

 

 

 

Number of
shares

 

 

Weighted
average
exercise price

 

Options exercisable as of December 31, 2023

 

 

321,796

 

 

$

4.39

 

Options vested and expected to vest as of December 31, 2023

 

 

321,796

 

 

$

4.39

 

 

The intrinsic value represents the total pre-tax intrinsic value and is calculated as the difference between the market value as reported by NASDAQ on December 31, 2023 of $3.44 and the exercise price of the in-the-money shares. During 2023, the total pre-tax intrinsic value of options exercised was negligible. The weighted average remaining contractual life of options exercisable was 4.53 years, and the weighted average remaining contractual life of options expected to vest was 4.53 years as of December 31, 2023.

Stock-Based Compensation

Stock-based compensation expense for stock options is estimated at the grant date based on each option’s fair value as calculated by the Black-Scholes model. The Black-Scholes model was developed for use in estimating the fair value of short-lived exchange traded options that have no vesting restrictions and are fully transferable. In addition, option pricing models require the input of highly subjective assumptions, including the expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends.

The Company uses historical volatility as management believes it is more representative of future stock price trends than implied volatility due to the relatively small number of actively traded options on the Company’s ordinary shares available to determine implied volatility. The Company estimates an expected term of options granted based upon the Company’s historical exercise and cancellation data for vested options. In addition, separate groups of employees that have similar exercise behavior are considered separately. The expected term of employee stock purchase plan shares is the average of the remaining purchase periods under each offering period. The Company bases the risk free interest rate used in the option valuation model on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. The Company does not anticipate paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero in the option valuation model. The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest.

The fair values of stock-based payment awards were estimated using the Black-Scholes option pricing model with the following assumptions:

 

 

 

Years ended December 31,

 

Stock Options:

 

2023

 

 

2016

 

Expected term in years

 

 

4.25

 

 

 

4.75

 

Weighted average risk-free interest rate

 

 

1.02

%

 

 

1.30

%

Expected dividend rate

 

 

%

 

 

%

Volatility

 

 

55.21

%

 

 

51.6

%

 

At December 31, 2023, there was approximately $0.1 million of total unrecognized compensation cost, as measured, related to unvested stock options and restricted stock and restricted stock units, which is expected to be recognized over a weighted-average period of 0.07 years.

 

At December 31, 2022, there was approximately $0.3 million of total unrecognized compensation cost, as measured, related to unvested stock options and restricted stock and restricted stock units, which is expected to be recognized over a weighted-average period of 0.88 years.

The following table summarizes the stock-based compensation expense recognized in the Company’s Consolidated Statements of Comprehensive Loss:

 

 

 

Years Ended December 31,

 

 

 

2023

 

 

2022

 

 

2021

 

 

 

(in thousands)

 

Cost of net sales

 

$

28

 

 

$

97

 

 

$

87

 

Selling, general and administrative

 

 

151

 

 

 

258

 

 

 

236

 

Research and development

 

 

114

 

 

 

248

 

 

 

181

 

Total

 

$

293

 

 

$

603

 

 

$

504